Nov 2026· COVID· Vol 6, pp. 197· 0 citations· 23 references
TL;DR
This Peruvian cohort documents how tocilizumab was used, in terms of timing and dose, during the first pandemic wave in a resource-constrained setting, during 2020, before randomized clinical trial evidence supporting its use became available.
Abstract
Background: Tocilizumab was used as emergency treatment for COVID-19 in Peru during 2020, before randomized clinical trial evidence supporting its use became available. Documenting real-world experiences of its implementation in resource-constrained health systems provides relevant insights for pandemic preparedness. Methods: Retrospective cohort study of 242 patients hospitalized with COVID-19 who received tocilizumab at seven sites in Peru (March–September 2020). Clinical characteristics, tocilizumab use, and adverse events were described (primary objective). A Cox proportional-hazards model was used as a secondary analysis to explore the association between tocilizumab initiation within the first 3 days of hospitalization (days 1–3) vs. later and all-cause mortality. Results: 79.8% (n = 193) patients were male; mean age was 59.0 years (SD: 13.0); 43.0% died. The median cumulative tocilizumab dose was 400 mg (IQR: 400–600 mg), lower than the currently recommended weight-based regimen (8 mg/kg; maximum 800 mg per infusion); 86.4% received a single dose. In the adjusted Cox model, early tocilizumab use was not significantly associated with mortality (HR: 1.09; 95%CI: 0.67–1.75; p = 0.72). The proportional-hazards assumption was met globally. Adverse events of any cause (not assessed for causality) were recorded during hospitalization in 56 (23.1%) patients; the most frequent MedDRA category was respiratory, thoracic, and mediastinal disorders (n = 16). Conclusions: This Peruvian cohort documents how tocilizumab was used, in terms of timing and dose, during the first pandemic wave in a resource-constrained setting. In the absence of an untreated comparator, these data do not allow inferences on the contribution of tocilizumab to mortality, ICU admission, or adverse events.
It is suggested that Remdesivir should be considered a preferred option in the treatment of severe cases of COVID-19 in Brazil, supporting the formulation of public health policies.
G. M. Houvèssou, Gary Joseph, M. Mahoche· Ciência & Saúde Coletiva· 0 citations
BACKGROUND
Among critically ill patients infected by the Omicron variant of coronavirus disease 2019 (COVID-19), the impact of COVID-19 vaccination on outcomes varied.
METHODS
A retrospective cohort study including adults with active COVID-19 admitted to dedicated intensive care units was conducted at a medical cente...
Cong-Tat Cia, Jen-Chieh Lee, N. Lee et al.· Journal of microbiology, imm...· 0 citations
CRAB isolation was associated with higher in-hospital mortality after adjustment for baseline severity, but selective sampling precludes causal inference, which suggests early detection suggests frequent carriage on admission.
Background: During the pandemic, methylene blue emerged as a repurposed drug for the treatment of COVID-19. The objective was to evaluate clinical outcomes of parenteral methylene blue use in hospitalized COVID-19 patients.
Methodology: A retrospective cohort study was conducted at COVID-19 hospitals in Rajkot, during...
K. Piparva, Bhavesh R. Kanabar, Anil P. Singh· National journal of medical...· 0 citations
Abstract Background Patients who were immunocompromised were largely excluded from COVID-19 clinical trials, and real-world evidence on remdesivir effectiveness has produced conflicting results. We evaluated whether early remdesivir initiation (vs late or never) reduces in-hospital mortality among patients who are immu...
Kathleen E. Hurwitz, Mark Berry, EunYoung Lee et al.· Open Forum Infectious Diseas...· 0 citations
Background:
The development of vaccines has played a significant role in managing the pandemic of COVID-19. The objective of this study was to investigate the impact of COVID-19 vaccination on mortality and intensive care unit (ICU) admissions.
Methods:
This retrospective, single-center cohort study included hospitaliz...
Julian Madrid· Chulalongkorn Medical Journa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.